Other languages Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
19.22 ^USD	-1.23%		+6.90%	+0.42%

20/03	Myriad Genetics Gets US Patent for SneakPeek Snap Device	MT
27/02	Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024	28/02
Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024	28/02
Myriad Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Myriad Genetics Acquires Intermountain Precision Genomics' Assets from Intermountain Health	01/02
Myriad Genetics, Inc. completed the acquisition of select assets of laboratory business of Intermountain Precision Genomics.	01/02
Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024	31/01
Myriad Genetics Agrees to Acquire Select Assets of Intermountain Precision Genomics' Laboratory Business	19/01
Myriad Genetics Names Scott Leffler as Chief Financial Officer, Reiterates Outlook	21/12
Myriad Genetics, Personalis Collaborate to Market ImmunoID NeXT Platform	17/11
Myriad Genetics, Inc. and Personalis, Inc. Partner to Market Solutions to Pharma Customers	17/11
Myriad Genetics Shares Climb as Q3 Loss Narrower Than Estimated, FY Revenue Guidance Raised	07/11
Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024	07/11
Myriad Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Myriad Genetics Insider Sold Shares Worth $470,622, According to a Recent SEC Filing	04/11
Myriad Genetics Names Sam Raha as Chief Operating Officer	01/11
Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023	01/11
Qiagen, Myriad Genetics Sign Collaboration Deal for Cancer Diagnostic Tests	26/23/26
Myriad Genetics, Qiagen to Develop Companion Diagnostic Tests for Cancer	26/23/26
QIAGEN and Myriad Genetics Partner to Advance Companion Diagnostics Development for Cancer	26/23/26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Other languages

Filters